Biotech Funding Rose 42% in 2006: An Interview with Ernst & Young’s Sarazen

Biotech revenues hit $70 billion last year, as the pace of mergers and acquisitions picks up. For more, read this brief update, and listen to Ernst & Young's resident expert, Scott Sarazen. Ernst Young released its annual biotech review today.

Play Video

Biotech in 2006: "The Year of the Deal" - An Interview with Ernst & Young's Biotech Markets Leader Scott Sarazen - Bloomberg

Bloomberg - (BLOOM)

Apr. 17, 2007. 01:04 PM EST

60% premiums were paid for some technologies